Envoy Medical GAAP EPS of -$0.08, revenue of $0.03M

* Envoy Medical press release [https://seekingalpha.com/pr/20509011-envoy-medical-reports-landmark-accomplishments-advancing-toward-fda-approval-of-first-of-its] (COCH [https://seekingalpha.com/symbol/COCH]): Q1 GAAP EPS of -$0.08.
* Revenue of $0.03M.
*
R&D expenses for the three months ended March 31, 2026, were $3,642 compared to $2,748 for the three months ended March 31, 2025. This increase of $894 mainly reflects additional clinical trial activity and related personnel costs during enrollment.

Sales and marketing expenses for the three months ended March 31, 2026, were $164 compared to $358 for the three months ended March 31, 2025. The decrease of $194 is primarily due to the reallocation of resources to research and development activities in support of the clinical trial.

MORE ON ENVOY MEDICAL

* Envoy Medical GAAP EPS of -$1.23, revenue of $0.02M [https://seekingalpha.com/news/4567572-envoy-medical-gaap-eps-of-1_23-revenue-of-0_02m]
* Envoy Medical announces pricing of up to $78M public offering [https://seekingalpha.com/news/4550289-envoy-medical-announces-pricing-of-up-to-78m-public-offering]
* Seeking Alpha’s Quant Rating on Envoy Medical [https://seekingalpha.com/symbol/COCH/ratings/quant-ratings]
* Historical earnings data for Envoy Medical [https://seekingalpha.com/symbol/COCH/earnings]
* Financial information for Envoy Medical [https://seekingalpha.com/symbol/COCH/income-statement]